Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Feb 4, 2010

Premium

Title: Bioinformatically Detectable Group of Novel Regulatory Oligonucleotides and Uses Thereof

Patent Number: 7,655,785

Filed: April 2, 2004

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The invention, the patent's abstract states, "relates to a first group of novel oligonucleotides, here identified as genomic address [messengers] or GAM [oligonucleotides], and a second group of novel operon-like polynucleotides, here identified as [genomic records] or GR [polynucleotides]. GAM oligonucleotides selectively inhibit translation of known target genes, many of which are known to be involved in various diseases.

"Nucleic acid molecules are provided respectively encoding 15,454 GAM precursor oligonucleotides, and 681 GR polynucleotides, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting GAM oligonucleotides and GR polynucleotides and specific functions and utilities thereof, for detecting expression of GAM oligonucleotides and GR polynucleotides, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof," the abstract notes.


Title: siRNA Targeting DNA-Damage-Inducible Transcript 4

Patent Number: 7,655,788

Filed: July 24, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to DDIT4."


Title: siRNA Targeting Transient Receptor Potential Cation Channel, Subfamily V, Member 1

Patent Number: 7,655,789

Filed: Oct. 26, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TRPV1."


Title: Oligonucleotides for Modulating Target RNA Activity

Application Number: 20100021914

Filed: Nov. 23, 2007 PCT Filed: Nov. 23, 2007

Inventor: Thorleif Moller, Stealth Biotech

The invention, the patent application's abstract states, "describes oligonucleotides that bind to microRNA target sites in target RNAs, such as mRNAs. The oligonucleotides of the invention may mediate RNase H degradation of the target RNA, mediate RNAi of the target RNA, or prevent microRNA regulation of the target RNA. The oligonucleotides of the invention are useful, e.g., as research tools for studying microRNA-mRNA interactions and for therapeutic development.

"The … invention also describes methods of identifying microRNA target sites, methods of validating microRNA target sites, methods of identifying oligonucleotides of the invention, and methods of modulating the activity of a target RNA using the oligonucleotides of the invention," the abstract adds.


Title: siRNA Targeting Ras-Related Nuclear Protein RAN

Application Number: 20100022413

Filed: Sept. 11, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."


Title: Methods and Compositions for the Treatment of Eye Disorders with Increased Intraocular Pressure

Application Number: 20100022623

Filed: Sept. 21, 2009

Lead Inventor: Ana Jimenez, Sylentis

The invention, the patent application's abstract states, "relates to methods and compositions that decrease intraocular pressure of the eye. The compositions of the invention comprise short interfering nucleic acid molecules including, but not limited to, siRNA that decrease expression of genes associated with production or drainage of intraocular fluid. The compositions of the invention can be used in the preparation of a medicament for the treatment of an eye conditions displaying increased IOP such as glaucoma, infection, inflammation, uveitis, and diabetic retinopathy. The methods of the invention comprise the administration to a patient in need thereof an effective amount of one or more siNAs of the invention."


Title: Methods of Treating Smooth Muscle Cell Disorders

Application Number: 20100022624

Filed: Sept. 25, 2009

Lead Inventor: Eric Verdin, University of California, San Francisco

The invention "provides methods of detecting cells showing smooth muscle differentiation," according to the patent application's abstract. "The … invention further provides methods of detecting tumor cells … [as well as] compositions and methods for treating smooth muscle cell disorders."


Title: siRNA Targeting Kinase Insert Domain Receptor

Application Number: 20100022763

Filed: Sept. 3, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for KDR."


Title: Long Interfering Nucleic Acid Duplexes Targeting Multiple RNA Targets

Application Number: 20100022618

Filed: Sept. 5, 2008

Lead Inventor: Dong Liang, Agave Pharma

The invention, the patent application's abstract states, comprises "long interfering nucleic acid duplexes, which are at least 30 nucleotides in length … [and have] at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA."

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.